Valuation: Imugene Limited

Market Cap 17.14M 12.08M 10.83M 10M 9.06M 16.9M 1.15B 120M 47.69M 604M 45.36M 44.41M 1.91B P/E 2027 *
-0.63x
P/E 2028 * -0.91x
Enterprise Value 8.34M 5.88M 5.27M 4.87M 4.41M 8.22M 560M 58.18M 23.21M 294M 22.07M 21.61M 927M EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
73.9%
Yield 2027 *
-
Yield 2028 * -
1 day-2.78%
1 week-2.78%
Current month-16.67%
1 month-20.45%
3 months-61.11%
6 months-73.08%
Current year-90.41%
1 week 0.03
Extreme 0.034
0.04
1 month 0.03
Extreme 0.032
0.05
Current year 0.03
Extreme 0.032
0.41
1 year 0.03
Extreme 0.032
0.41
3 years 0.03
Extreme 0.032
5.1
5 years 0.03
Extreme 0.032
21.25
10 years 0.03
Extreme 0.032
21.25
Manager TitleAgeSince
Director of Finance/CFO - 04/03/2025
Chief Tech/Sci/R&D Officer - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/06/2022
Director TitleAgeSince
Chairman 70 31/10/2012
Director/Board Member 66 23/04/2019
Director/Board Member 61 07/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
19/12/25 Free

Director

29,411 0.0093%
19/12/25 Free

Director

14,706 0.0047%
19/12/25 Free

Director

29,411 0.0093%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-2.78%-91.03%-97.49% 12.4M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.82%-0.38%+37.84%+136.79% 38.04B
Weighted average by Cap. +3.23%-0.29%+47.55%+161.46%

Financials

2027 *2028 *
Net sales - -
Net income -36.17M -25.49M -22.85M -21.1M -19.12M -35.66M -2.43B -252M -101M -1.27B -95.72M -93.72M -4.02B -28.65M -20.19M -18.1M -16.71M -15.14M -28.25M -1.92B -200M -79.72M -1.01B -75.83M -74.24M -3.19B
Net Debt -8.8M -6.2M -5.56M -5.13M -4.65M -8.68M -591M -61.39M -24.49M -310M -23.29M -22.8M -979M 8.5M 5.99M 5.37M 4.96M 4.49M 8.38M 571M 59.3M 23.65M 299M 22.5M 22.03M 945M
Projected Income Statement - Annual - Imugene Limited
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
14
Date Price Change Volume
28/10/26 $0.0350 -2.78% 918,845
27/10/26 $0.0360 +2.86% 911,004
26/10/26 $0.0350 -7.89% 1,881,028
23/10/26 $0.0380 -2.56% 2,122,778
22/10/26 $0.0390 +5.41% 2,102,517
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Imugene Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0350AUD
Average target price
0.2300AUD
Spread / Average Target
+557.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Imugene Limited